Key Takeaways & Executive Findings
- •• A population pharmacokinetic model for carbamazepine in Chinese epileptic patients was developed, identifying body weight, age, and CYP3A5*3 genotype as significant covariates affecting clearance. • CYP3A5*3 carriers exhibited 20% lower carbamazepine clearance, suggesting a need for dose adjustment in this genotype group. • The model provides a basis for individualized carbamazepine dosing in Chinese patients, potentially improving therapeutic outcomes and reducing adverse effects. • The study highlights the importance of pharmacogenetic factors in antiepileptic drug therapy and supports the integration of PopPK modeling in clinical practice.
Abstract
Background and Objective: Carbamazepine (CBZ) is a first-line antiepileptic drug with narrow therapeutic index and high interindividual variability. This study aimed to develop a population pharmacokinetic (PopPK) model of CBZ in Chinese patients with epilepsy and to identify factors affecting its disposition. Methods: A prospective study was conducted in 120 Chinese patients with epilepsy receiving CBZ monotherapy. Blood samples were collected at steady state, and CBZ concentrations were measured using a validated HPLC method. Population pharmacokinetic analysis was performed using NONMEM 7.4. Covariate analysis included demographic, clinical, and genetic factors (CYP3A4*1B, CYP3A5*3, ABCB1 C3435T). Results: A one-compartment model with first-order absorption and elimination adequately described the data. Typical values of apparent clearance (CL/F) and volume of distribution (V/F) were 3.42 L/h and 1.12 L/kg, respectively. Significant covariates included body weight, age, and CYP3A5*3 genotype. CL/F increased with body weight and decreased with age; CYP3A5*3 carriers had 20% lower CL/F compared to non-carriers. Interindividual variability in CL/F was 28.5%. Model evaluation via bootstrap and visual predictive check confirmed stability and predictive performance. Conclusions: A PopPK model of CBZ in Chinese epileptic patients was successfully developed. Body weight, age, and CYP3A5*3 genotype significantly influence CBZ clearance, which may guide individualized dosing. Further studies are warranted to validate the model in larger populations and explore other genetic variants.
1. Introduction
Carbamazepine (CBZ) is one of the most widely prescribed antiepileptic drugs for the treatment of partial and generalized tonic-clonic seizures. Despite its efficacy, CBZ has a narrow therapeutic index and exhibits significant interindividual pharmacokinetic variability, which complicates dosing and increases the risk of toxicity or suboptimal response. Factors such as age, body weight, concomitant medications, and genetic polymorphisms in drug-metabolizing enzymes and transporters have been implicated in this variability.
Population pharmacokinetic (PopPK) modeling is a powerful tool to quantify and explain such variability, enabling the identification of patient-specific covariates that influence drug disposition. Several PopPK models of CBZ have been developed in different populations, but data specific to Chinese patients are limited. Given ethnic differences in drug metabolism and genetic backgrounds, it is essential to establish a model tailored to this population.
This study aimed to develop a PopPK model for CBZ in Chinese patients with epilepsy, incorporating demographic, clinical, and pharmacogenetic covariates. The ultimate goal is to provide a basis for individualized dosing, thereby enhancing therapeutic efficacy and safety.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Li, J. Chen, X. Liu (2026). Pharmacokinetics of Carbamazepine in Chinese Patients with Epilepsy: A Population Pharmacokinetic Analysis. Chinese Journal of New Drugs. https://doi.org/10.1007/s40262-025-01432-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the significance of CYP3A5*3 genotype in carbamazepine dosing?
CYP3A5*3 carriers have reduced enzyme activity, leading to lower carbamazepine clearance. This may require dose reduction to avoid toxicity, as indicated by the 20% lower clearance observed in this study.
How does body weight affect carbamazepine clearance?
Carbamazepine clearance increases with body weight, meaning heavier patients may require higher doses to achieve therapeutic concentrations. The model provides a quantitative relationship to guide dosing.
What is the typical half-life of carbamazepine in Chinese patients?
Based on the model, the typical half-life is approximately 12-15 hours, but it varies with age, weight, and genotype. Individualized estimates can be obtained using the PopPK model.
Can this model be used for therapeutic drug monitoring?
Yes, the model can be integrated into Bayesian forecasting tools to predict individual concentrations and optimize dosing, especially in patients with unusual clinical characteristics.
What are the limitations of this study?
The study was conducted in a single center with a relatively small sample size. Validation in larger, multi-center cohorts and inclusion of other genetic variants are needed to confirm the findings.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.